Adjuvant sunitinib or sorafenib don’t prevent recurrence of kidney cancer

Results from the ASSURE clinical trial have recently been published in the Lancet. ASSURE┬ácompared the effect of adjuvant sorafenib or sunitinib with placebo in renal cell carcinoma (RCC) patients who had had their tumours surgically removed, and who had a high risk for recurrence. The trial was conducted in the US and Canada, and initial […]

read more

Immunotherapy before and after surgery for kidney cancer

At the American Urological Association’s Annual Meeting in San Diego this week, Dr Harshman spoke about treating renal cell carcinoma (RCC) before and after surgery with immunotherapy. Although results from the EVEREST trial and others are eagerly anticipated, there has been no major success using adjuvant therapies (treatment after surgery) in kidney cancer to date. […]

read more

Adjuvant sunitinib or sorafenib for high risk kidney cancer

A study published in The Lancet last week reported that adjuvant treatment (treatment following surgery) with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treatment discontinuation occurred because of excessive toxicity, despite dose reductions. These results provide a strong […]

read more
Showing 31 to 33 of 33 results
  TOP